Kristin Brown
Has grant
Senior Research Fellow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Investigating the role of cellular metabolism in regulating antigen presentation and tumour immune escape
Open Date: 2021-11-04
Close Date:
Grant: Close
Investigating the consequences of dysregulated lipogenesis in cancer
Open Date: 2021-01-01
Close Date: 2023-12-31
Grant: Close
Targeting cell metabolism to circumvent chemotherapy resistance in TNBC
Open Date: 2018-10-11
Close Date: 2021-10-10
Grant: Close
Targeting cell metabolism to improve the treatment of triple-negative breast cancer
Open Date: 2018-04-01
Close Date: 2022-03-01
Grant: Close
Interplay between metabolic reprogramming and oncogenic signalling in the cellular response to chemotherapy
Open Date: 2018-01-01
Close Date: 2020-12-31
Articles (10)
Year:
2026
Chronic exposure of local fibroblasts to the reactive tumour niche results in the emergence of cancer-associated fibroblasts (CAFs), which can be classed into multiple subtypes with distinct functional and molecular characteristics. Of these subtypes, myofibroblastic CAFs (myCAFs), contribute to tumour progression primarily by depositing and remodelling extracellular matrix (ECM) within the tumour microenvironment (TME). ECM production is known to be a metabolically demanding process, but specific metabolic pathways that are reprogrammed during myCAF activation are poorly understood. Here, we show that cholesterol biosynthesis is elevated in myCAFs relative to normal fibroblasts. We find that cholesterol is specifically enriched in the myCAF endoplasmic reticulum (ER) membrane and is associated with augmented ER mass and enhanced ER secretory function. Importantly, we demonstrate that pharmacological or genetic inhibition of cholesterol biosynthesis plays a critical role in regulating the ECM-secreting and ECM remodelling function of myCAFs. Moreover, we show that inhibition of cholesterol biosynthesis in myCAFs markedly constrains mammary tumour metastasis in vivo . These studies suggest that cholesterol biosynthesis represents a metabolic vulnerability that can be exploited to normalise myCAF-mediated ECM dysfunction in the TME.
Year:
2026
Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that plays a role in the regulation of redox homeostasis and cellular metabolism. Activating mutations in the NRF2 pathway have been identified in approximately 15% of liver cancer patients. However, the mechanisms by which NRF2 promotes liver tumorigenesis are poorly understood. Employing a transgenic zebrafish model with hepatocyte-specific, inducible expression of a clinically relevant constitutively active NRF2 mutant (NRF2 T80K ), we show that constitutive activation of NRF2 drives hepatocyte to cholangiocyte transdifferentiation. Importantly, we demonstrate that NRF2 affects liver cell plasticity in a cell-autonomous, evolutionarily conserved, and reversible manner. Utilizing an epigenetic-focused chemical screen, the BRG1/BRM inhibitor FHD-286 was identified as a potent suppressor of NRF2-driven transdifferentiation. Overall, our study reveals a novel role for NRF2 in the regulation of liver cell plasticity during tumour initiation and identifies a therapeutic approach to overcome the oncogenic activity of NRF2.
Year:
2026
Cancer-associated cachexia is a severe metabolic syndrome marked by dramatic loss of adipose and muscle mass. Although preclinical models have advanced our understanding of cachexia, there are still no approved therapies due to the limited insights into the mechanisms underlying tissue wasting. Here, we utilise a YAP-driven model of liver cancer in zebrafish, which rapidly develops cachexia, to uncover an evolutionarily conserved role for bile acid disruption in the onset of cachexia. Spatial transcriptomic analysis revealed that YAP induces a bi-lineage cholangiocarcinoma phenotype, which was associated with bile acid dysregulation. Mechanistically, we establish that both bile acid synthesis (via CYP7A1) and signalling through the bile acid receptor TGR5 are essential for cachexia induction. Notably, we find that the promotion of bile acid excretion with odevixibat ameliorates cachexia. Together, our findings reveal an evolutionarily conserved mechanism by which YAP promotes cachexia and suggest a potential therapeutic strategy to treat the syndrome.
Year:
2026
The anti-apoptotic protein MCL-1 (myeloid cell leukemia-1) is essential for embryogenesis and the survival of many cell types that tolerate loss of its relatives, BCL-XL and BCL-2. Apoptosis-unrelated roles of MCL-1 in metabolism may contribute to this requirement, although their relevance for embryogenesis and postnatal life remains unclear. We hypothesized that BCL-XL and BCL-2 may substitute MCL-1’s anti-apoptotic but not its apoptosis-unrelated functions. Replacing MCL-1 with BCL-XL or BCL-2 supported embryo development by rescuing the Mcl-1 −/− preimplantation lethality. Mcl-1 Bcl-xL/Bcl-xL but not Mcl-1 Bcl-2/Bcl-2 mice were born on a mixed background, although they showed metabolic defects. Thus MCL-1’s apoptosis-unrelated functions appear critical in later development, with BCL-XL, but not BCL-2, partially compensating. These findings clarify MCL-1’s distinct physiological roles, critically informing MCL-1 inhibitor development as cancer therapeutics.
Year:
2025
Year:
2025
Year:
2025
Recent evidence has highlighted the importance of employing culture media designed to emulate the metabolic environment Here, we utilize the physiological medium Plasmax to examine the impact of nutrient availability on the human hepatocyte cell line, HepG2. Incubation of HepG2 cells in Plasmax suppressed a transcriptional program driven by Hepatocyte Nuclear Factor 4 (HNF4A), a master regulator of hepatocyte identity. Given that HepG2 cells were originally isolated from a patient with hepatoblastoma, this suggests reversion to the native state in physiological media. Importantly, exclusion of iron from Plasmax reinstated the HNF4A-driven transcriptional program. These studies suggest a relationship between iron availability and the fidelity of hepatocyte cell fate and highlight the importance of more faithfully recapitulating in vivo metabolite availability in vitro .
Year:
2025
Year:
2024
Year:
2023
Collaborators (12)
Kate McArthur
Lab Head
MONASH UNIVERSITY
Yingzi Yang
Professor
Harvard University
Andrew Cox
Group Leader
Peter MacCallum Cancer Institute
Martin Pal
Charles Sturt University
Lev M. Kats
Group Leader
Peter MacCallum Cancer Institute
Sheik Nadeem Elahee Doomun
University of Melbourne
Jason Powell
Head, Cancer Cell Signalling Unit, Molecular Signalling Laboratory
University of South Australia
Andrew H. Wei
Stream Lead- Acute Leukaemia and MDS
Peter MacCallum Cancer Institute
Kimberley Evason
Associate Professor
University of Utah
Thomas Cox
Laboratory Head (Faculty) - Matrix & Metastasis
Garvan Institute of Medical Research
Marco Herold
Chief Executive Officer
Olivia Newton-John Cancer Research Institute
Tim Thomas
Professor
Walter and Eliza Hall Institute of Medical Research
Make your next move.
Prepare your application
Review drafts before you send them.